Avirmax CMC Inc. Launches AAV Production with Sf Rhabdovirus-free Cell Lines (Sf-RVF™)
23 Mar 2023
Gene Therapy
HAYWARD, Calif., March 22, 2023 /PRNewswire/ -- Avirmax CMC Inc. (ACI), a cGMP-licensed CDMO, is announcing the implementation of its newly-developed Sf rhabdovirus-free cell lines (under the generic trademark of Sf-RVF™) developed for producing recombinant adeno-associated viral vectors (rAAV).
Continue Reading
As an insect cell line derived from the ovarian tissue of Spodoptera frugiperda (Sf), the Sf9 cell line in concert with recombinant baculoviruses, has been widely utilized for manufacturing biologicals, including recombinant proteins, vaccines, and rAAV-based gene therapy vectors. The Sf9 cell rAAV production system has been shown to produce high yields of rAAV products containing vector genomes. However, Sf9 cell lines persistently carries Sf rhabdovirus (Sf-RV), an enveloped, negative sense and single stranded RNA (-ssRNA) virus. Although Sf-RV is an insect-specific virus and non-infectious to mammalian and human cell lines, using a Sf-RV containing Sf9 cell line for producing biologicals has potential viral safety risks that are required to be mitigated by international regulatory authorities during biopharmaceutical production.
Avirmax CMC Inc. Delivers rAAV Products with Higher Viral Safety Assurance Using Sf-RVF™ Cell Lines
Tweet this
When using serum-free suspension culture, Avirmax CMC's Sf-RVF™ cell lines have been shown to be comparable with respect to rAAV yields and quality, relative to rAAV produced using Sf-RV parental cell lines. "By implementing our Sf-RVF™ cell lines, the Sf-RV safety margin of biologic product has been increased by more than 1 billion-fold", commented Shengjiang Shawn Liu, Ph.D., DVM, chief executive and scientific officer of the company. Avirmax CMC Inc. is now using the Sf-RVF™ cell lines in rAAV manufacturing for research and clinical development purposes. Avirmax CMC Inc. is also expanding the Sf-RVF™ cell lines to the production of other modalities including vaccines and protein drugs.
Avirmax CMC Inc. (ACI) is a subsidiary of Avirmax Inc., a San Francisco Bay Area based firm working on technological solutions to challenges associated with rAAV manufacturing and testing. Please visit us at www.avirmaxCMC.com for more information.
Contact
Please contact
June Song, Associate Director for Operations
Email : [email protected]
Tel: +1-510-641-0201
Address
25503 Whitesell Street
Hayward 94545 CA
USA
SOURCE Avirmax
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.